Phase II Interstitial Brachytherapy Combined With Androgen Deprivation Therapy for Locally Recurrent Prostate Cancer After Prior External Beam Irradiation
- Determine the feasibility and patient tolerance of interstitial brachytherapy combined
with androgen-deprivation therapy for patients with locally recurrent prostate cancer
after prior external-beam irradiation.
- Determine the toxicity of interstitial brachytherapy combined with androgen-deprivation
therapy in these patients.
- Determine the tumor response to interstitial brachytherapy combined with
androgen-deprivation therapy in these patients.
OUTLINE: Patients receive neoadjuvant therapy comprising leuprolide acetate intramuscularly
for 3 months and oral bicalutamide once daily for 30 days, beginning on the first day of
leuprolide acetate administration. Patients then undergo interstitial brachytherapy
implantation with I-125. Following brachytherapy, patients receive adjuvant leuprolide
acetate every 3 months for an additional 6 months.
Quality of life is assessed at baseline and at every treatment and follow-up visit.
After completion of study therapy, patients are followed every 3 months for 2 years, every
to 4-6 months for 3 years, and then annually thereafter.
Primary Purpose: Treatment
William W. Wong, MD
United States: Federal Government
|Mayo Clinic in Arizona||Scottsdale, Arizona 85259-5404|